Receive the latest updates from Matrix Medical in real time to understand product information.

The 11th China Valve (Hangzhou) Conference was successfully concluded in Hangzhou from April 14th to 20th, 2025. During this period, the special session of "National Key Laboratory for Transvascular Implantation Devices", led by Professor Wang Jian'an, an academician of the CAS Member and hosted by the Second Affiliated Hospital of Zhejiang University School of Medicine, was held in the morning of the 20th. The conference is not only a milestone for China's medical devices to move from "manufacturing" to "intelligent manufacturing", but also regarded as a technological indicator for the global cardiovascular intervention field.

The venue was packed with top scholars and industry leaders from around the world discussing the future of innovation. As a special guest, Ji Peihong, CEO of Matrix Medical, delivered a keynote speech titled "Research and Development of a New Coronary Artery Remodeling Catheter", fully disclosing for the first time the innovative product independently developed by the company - Coronary Artery Remodeling Catheter. This product is based on the concept of "intervention without implantation" of Matrix Medical, providing a new clinical treatment path for vascular injury repair, with the following advantages:

1.The natural support generated in situ maintains the natural anatomy and physiological structure of blood vessels, and inhibits rebound

2.No foreign body implantation to avoid restenosis

3.Can maintain long-term vascular lumen openness and keep blood flowing smoothly

4.No need for lifelong medication for minimally invasive treatment, minimal damage to patients

There is no need for lifelong medication for minimally invasive treatment, and the damage to patients is minimal. "Our pursuit is not only to replace imports, but also to create new treatment methods," Ji Peihong emphasized in her speech. The research results of the Matrix Medical team are redefining the technical boundaries of coronary intervention. This not only reflects the leap of Matrix Medical from traditional "instrument manufacturing" to high-end "instrument intelligent manufacturing", but also a vivid practice of the concept of "intervention without implantation".

The project has been successfully launched into clinical trials, and at the same time, there is a deep strategic collaboration between Juzheng Medical and Zhejiang Medical Second Hospital's Vascular Implant Device Research Institute. The multi million level cooperation agreement signed by both parties on December 18, 2024 has included the coronary artery remodeling system in the key research and development plan of "2030 Healthy China".

This academic storm that began in Hangzhou not only marks a technological awakening in the field of vascular intervention in China, but also heralds a profound change in the global cardiovascular treatment landscape. When the concept of "no implantation" is implemented in reality, millions of coronary heart disease patients will usher in a new dawn of treatment.

In the future, Matrix Medical takes solving clinical pain points as the first starting point, continues to adhere to the concept of "intervention without implantation", truly provides new "Chinese original treatment solutions" for vascular intervention treatment patients, and continuously injects innovative power into the medical and health industry.